Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 8098561, 12 pages
http://dx.doi.org/10.1155/2016/8098561
Research Article

Electroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNS

1Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China
2Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

Received 1 November 2015; Accepted 30 December 2015

Academic Editor: Mohamed M. Abdel-Daim

Copyright © 2016 Xinyue Jing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Hevener, J. M. Olefsky, D. Reichart et al., “Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones,” Journal of Clinical Investigation, vol. 117, no. 6, pp. 1658–1669, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Picard and J. Auwerx, “PPARγ and glucose homeostasis,” Annual Review of Nutrition, vol. 22, pp. 167–197, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Shimizu, T. Tsuchiya, N. Sato, Y. Shimomura, I. Kobayashi, and M. Mori, “Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients,” Diabetes Care, vol. 21, no. 9, pp. 1470–1474, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Darbandi, M. Darbandi, P. Mokarram et al., “Effects of body electroacupuncture on plasma leptin concentrations in obese and overweight people in Iran: a randomized controlled trial,” Alternative Therapies in Health and Medicine, vol. 19, no. 2, pp. 24–31, 2013. View at Google Scholar · View at Scopus
  6. L. Rerksuppaphol, “Efficacy of auricular acupressure combined with transcutaneous electrical acupoint stimulation for weight reduction in obese women,” Journal of the Medical Association of Thailand, vol. 95, supplement 12, pp. S32–S39, 2012. View at Google Scholar · View at Scopus
  7. Q. Wang, W.-H. Li, Q.-H. Zhou, X.-D. Tang, X.-X. Zhang, and S. Shu, “Weight reduction effects of acupuncture for obese women with or without perimenopausal syndrome: a pilot observational study,” The American Journal of Chinese Medicine, vol. 40, no. 6, pp. 1157–1166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Wang, D. R. Tian, P. Tso, and J. S. Han, “Arcuate nucleus of hypothalamus is involved in mediating the satiety effect of electroacupuncture in obese rats,” Peptides, vol. 32, no. 12, pp. 2394–2399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gong, X. Wang, Z. Mao, Q. Shao, X. Xiang, and B. Xu, “Effect of electroacupuncture on leptin resistance in rats with diet-induced obesity,” The American Journal of Chinese Medicine, vol. 40, no. 3, pp. 511–520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Ji, J. Hu, and S. Ma, “Effects of electroacupuncture Zusanli (ST36) on food intake and expression of POMC and TRPV1 through afferents-medulla pathway in obese prone rats,” Peptides, vol. 40, pp. 188–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. T. Cabıoğlu and N. Ergene, “Electroacupuncture therapy for weight loss reduces serum total cholesterol, triglycerides, and LDL cholesterol levels in obese women,” The American Journal of Chinese Medicine, vol. 33, no. 4, pp. 525–533, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. D. Rosen, P. Sarraf, A. E. Troy et al., “PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Escher, O. Braissant, S. Basu-Modak, L. Michalik, W. Wahli, and B. Desvergne, “Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding,” Endocrinology, vol. 142, no. 10, pp. 4195–4202, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. D. Rosen, R. N. Kulkarni, P. Sarraf et al., “Targeted elimination of peroxisome proliferator-activated receptor γ in β cells leads to abnormalities in islet mass without compromising glucose homeostasis,” Molecular and Cellular Biology, vol. 23, no. 20, pp. 7222–7229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Akazawa, F. Sun, M. Ito, E. Kawasaki, and K. Eguchi, “Efficacy of troglitazone on body fat distribution in type 2 diabetes,” Diabetes Care, vol. 23, no. 8, pp. 1067–1071, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Miyazaki, A. Mahankali, M. Matsuda et al., “Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 6, pp. 2784–2791, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Shadid and M. D. Jensen, “Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity,” Diabetes Care, vol. 26, no. 11, pp. 3148–3152, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. Smith, L. De Jonge, J. Volaufova, Y. Li, H. Xie, and G. A. Bray, “Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial,” Metabolism: Clinical and Experimental, vol. 54, no. 1, pp. 24–32, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Moreno, S. Farioli-Vecchioli, and M. P. Cerù, “Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS,” Neuroscience, vol. 123, no. 1, pp. 131–145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. D. A. Sarruf, F. Yu, H. T. Nguyen et al., “Expression of peroxisome proliferator-activated receptor-γ in key neuronal subsets regulating glucose metabolism and energy homeostasis,” Endocrinology, vol. 150, no. 2, pp. 707–712, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Mouihate, L. Boissé, and Q. J. Pittman, “A novel antipyretic action of 15-deoxy-Delta12,14-prostaglandin J2 in the rat brain,” Journal of Neuroscience, vol. 24, no. 6, pp. 1312–1318, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. P. De Vos, A.-M. Lefebvre, S. G. Miller et al., “Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma,” The Journal of Clinical Investigation, vol. 98, no. 4, pp. 1004–1009, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Rieusset, J. Auwerx, and H. Vidal, “Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, pp. 265–271, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Goetze, A. Bungenstock, C. Czupalla et al., “Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands,” Hypertension, vol. 40, no. 5, pp. 748–754, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. J. I. Lee, Y.-H. Paik, K. S. Lee et al., “A peroxisome-proliferator activated receptor-gamma ligand could regulate the expression of leptin receptor on human hepatic stellate cells,” Histochemistry and Cell Biology, vol. 127, no. 5, pp. 495–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. S. Ahima and J. S. Flier, “Leptin,” Annual Review of Physiology, vol. 62, pp. 413–437, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Vaisse, J. L. Halaas, C. M. Horvath, J. E. Dernell Jr., M. Stoffel, and J. M. Friedman, “Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice,” Nature Genetics, vol. 14, no. 1, pp. 95–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. S. H. Bates, W. H. Stearns, T. A. Dundon et al., “STAT3 signalling is required for leptin regulation of energy balance but not reproduction,” Nature, vol. 421, no. 6925, pp. 856–859, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. Q. Gao, M. J. Wolfgang, S. Neschen et al., “Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4661–4666, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Bjørbaek and B. B. Kahn, “Leptin signaling in the central nervous system and the periphery,” Recent Progress in Hormone Research, vol. 59, pp. 305–331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. J. Reed, K. Meszaros, L. J. Entes et al., “A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat,” Metabolism: Clinical and Experimental, vol. 49, no. 11, pp. 1390–1394, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, “Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening,” Pharmacological Research, vol. 52, no. 4, pp. 313–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Bonora, G. Targher, M. Alberiche et al., “Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity,” Diabetes Care, vol. 23, no. 1, pp. 57–63, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Hermansen and L. S. Mortensen, “Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus,” Drug Safety, vol. 30, no. 12, pp. 1127–1142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Fonseca, “Effect of thiazolidinediones on body weight in patients with diabetes mellitus,” American Journal of Medicine, vol. 115, supplement 8, pp. 42S–48S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. A. L. Werner and M. T. Travaglini, “A review of rosiglitazone in type 2 diabetes mellitus,” Pharmacotherapy, vol. 21, no. 9, pp. 1082–1099, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Chilcott, P. Tappenden, M. L. Jones, and J. P. Wight, “A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus,” Clinical Therapeutics, vol. 23, no. 11, pp. 1792–1823, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Vamecq and N. Latruffe, “Medical significance of peroxisome proliferator-activated receptors,” The Lancet, vol. 354, no. 9173, pp. 141–148, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in health and disease,” Nature, vol. 405, no. 6785, pp. 421–424, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. A. N. Howard, “The historical development, efficacy and safety of very-low-calorie diets,” International Journal of Obesity, vol. 5, no. 3, pp. 195–208, 1981. View at Google Scholar · View at Scopus
  43. N. Tian, F. Wang, D.-R. Tian et al., “Electroacupuncture suppresses expression of gastric ghrelin and hypothalamic NPY in chronic food restricted rats,” Peptides, vol. 27, no. 9, pp. 2313–2320, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. L. C. Pickavance, R. E. Buckingham, and J. P. H. Wilding, “Insulin-sensitizing action of rosiglitazone in enhanced by preventing hyperphagia,” Diabetes, Obesity and Metabolism, vol. 3, no. 3, pp. 171–180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Chaput, R. Saladin, M. Silvestre, and A. D. Edgar, “Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight,” Biochemical and Biophysical Research Communications, vol. 271, no. 2, pp. 445–450, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. Q. Wang, S. Dryden, H. M. Frankish et al., “Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y,” British Journal of Pharmacology, vol. 122, no. 7, pp. 1405–1410, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. D. A. Sarruf, F. Yu, H. T. Nguyen et al., “Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis,” Endocrinology, vol. 150, no. 2, pp. 707–712, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Lu, D. A. Sarruf, S. Talukdar et al., “Brain PPAR-γ promotes obesity and is required for the insuling-sensitizing effect of thiazolidinediones,” Nature Medicine, vol. 17, no. 5, pp. 618–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. M. W. Schwartz, S. C. Woods, D. Porte Jr., R. J. Seeley, and D. G. Baskin, “Central nervous system control of food intake,” Nature, vol. 404, no. 6778, pp. 661–671, 2000. View at Google Scholar · View at Scopus
  50. M. A. Pelleymounter, M. J. Cullen, M. B. Baker et al., “Effects of the obese gene product on body weight regulation in ob/ob mice,” Science, vol. 269, no. 5223, pp. 540–543, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. C. T. Montague, I. S. Farooqi, J. P. Whitehead et al., “Congenital leptin deficiency is associated with severe early-onset obesity in humans,” Nature, vol. 387, no. 6636, pp. 903–908, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. I. Sadaf Farooqi, G. Matarese, G. M. Lord et al., “Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency,” The Journal of Clinical Investigation, vol. 110, no. 8, pp. 1093–1103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. K. El-Haschimi, D. D. Pierroz, S. M. Hileman, C. Bjørbæk, and J. S. Flier, “Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1827–1832, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Satoh, Y. Ogawa, G. Katsuura et al., “The arcuate nucleus as a primary site of satiety effect of leptin in rats,” Neuroscience Letters, vol. 224, no. 3, pp. 149–152, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. R. J. Jacob, J. Dziura, M. B. Medwick et al., “The effect of leptin is enhanced by microinjection into the ventromedial hypothalamus,” Diabetes, vol. 46, no. 1, pp. 150–152, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. H. J. Grill, M. W. Schwartz, J. M. Kaplan, J. S. Foxhall, J. Breininger, and D. G. Baskin, “Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake,” Endocrinology, vol. 143, no. 1, pp. 239–246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Andò and S. Catalano, “The multifactorial role of leptin in driving the breast cancer microenvironment,” Nature Reviews Endocrinology, vol. 8, no. 5, pp. 263–275, 2012. View at Publisher · View at Google Scholar · View at Scopus